MAPS PBC Introduction by CEO Amy Emerson

The Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation leads efforts to establish MDMA-assisted psychotherapy as an approved prescription treatment. By prioritizing public benefit over narrow profit motives, the organization systematically navigates the FDA drug development process. Following promising late-phase results showing statistically significant symptom reduction among treatment-resistant populations, clinical focus has shifted toward confirmatory stage-three research studies. Beyond central trials, expanded access programs, sometimes referred to as compassionate use, facilitate broader therapeutic engagement as researchers work toward long-term approval. The organization also supports investigator-initiated studies, allowing external researchers to develop independent MDMA-focused programs with foundational expertise and supply support.